Ascendis Pharma will host informational booths, events, and presentations showcasing use of its innovative TransCon technology in the areas of growth hormone deficiency, hypoparathyroidism, achondroplasia, and Turner syndrome during ENDO 2024, the annual meeting of the Endocrine Society being held June 1-4, 2024, in Boston. “In addition to physician and caregiver presentations in pediatric GHD, we look forward to our first in-person opportunity to share data from foresiGHt, our pivotal trial of TransCon hGH in adults with GHD,” said Aimee Shu, M.D., Ascendis Pharma’s Senior Vice President of Clinical Development, Endocrine Medical Sciences. “And with World Hypoparathyroidism Day coinciding with the first day of ENDO, we are pleased to host an informational booth focused on deepening physician awareness of the significant health and quality-of-life impacts of hypoparathyroidism.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024
- Ascendis Pharma Expands Capital with Warrants and Shares
- Ascendis Pharma price target raised to $140 from $116 at Morgan Stanley
- Ascendis approval still likely despite PDUFA push out, says BofA
- FDA Delays Ascendis Pharma’s Drug Review
Questions or Comments about the article? Write to editor@tipranks.com